Immunotherapy with immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 and CTLA4 axis has transformed clinical outcomes for patients across several cancer histologies and has become an integral part of standard treatment regimens. This evidence concerns the gene CTLA4 and cancer.